title: Eradication of Helicobacter pylori Infection.
abstract: Helicobacter pylori infects about 50 % of the world's population, causing at a minimum chronic gastritis. A subset of infected patients will ultimately develop gastric or duodenal ulcer disease, gastric adenocarcinoma, or MALT (mucosa-associated lymphoid tissue) lymphoma. Eradication of H. pylori requires complex regimens that include acid suppression and multiple antibiotics. The efficacy of treatment using what were once considered standard regimens have declined in recent years, mainly due to widespread development of antibiotic resistance. Addition of bismuth to standard triple therapy regimens, use of alternate antibiotics, or development of alternative regimens using known therapies in novel combinations have improved treatment efficacy in specific populations, but overall success of eradication remains less than ideal. Novel regimens under investigation either in vivo or in vitro, involving increased acid suppression ideally with fewer antibiotics or development of non-antibiotic treatment targets, show promise for future therapy.
authors.affiliation: Department of Pediatrics, DGSOM at UCLA, Los Angeles, CA, USA. emarcus@mednet.ucla.edu.|VA GLAHS, 11301 Wilshire Blvd. Bldg 113 Rm 324, Los Angeles, CA, 90073, USA. emarcus@mednet.ucla.edu.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Marcus
authors.affiliation: Department of Physiology, DGSOM at UCLA, Los Angeles, CA, USA.|Department of Medicine, DGSOM at UCLA, Los Angeles, CA, USA.|VA GLAHS, 11301 Wilshire Blvd. Bldg 113 Rm 324, Los Angeles, CA, 90073, USA.
authors.forename: George
authors.initials: G
authors.lastname: Sachs
authors.affiliation: Department of Physiology, DGSOM at UCLA, Los Angeles, CA, USA.|VA GLAHS, 11301 Wilshire Blvd. Bldg 113 Rm 324, Los Angeles, CA, 90073, USA.
authors.forename: David R
authors.initials: DR
authors.lastname: Scott
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D002908:Chronic Disease; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D054328:Proton Pump Inhibitors / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D001729:Bismuth
keywords: Antibiotic resistance; Eradication; Gastric acid; Helicobacter pylori